Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.44 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.44 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.44 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.44 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.44 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.44 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.38 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.38 |
| ▸ | ITGAL | P20701 | 1/20 | 0.38 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HBB | P68871 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8131205 | 1.00 | CA2 (0.55) | CA2PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL11228569 | 0.86 | CA2 (0.52) | CA2PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL11484068 | 0.82 | CA2 (0.60) | CA2PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL1044700 | 0.81 | CA2 (0.38) | CA2PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL441033 | 0.81 | CA2 (0.59) | CA2FFAR1CA1ADRA1AHTR1A | |
| SCHEMBL15864966 | 0.81 | CA2 (0.38) | CA2PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL11026135 | 0.81 | CA2 (0.55) | CA2PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL1119121 | 0.81 | CA2 (0.58) | CA2PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL1044791 | 0.81 | CA2 (0.58) | CA2PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL29444759 | 0.81 | CA2 (0.58) | CA2PRKAB2PRKAG1PRKAA2PRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1768970-B1 | SULFAMATE AND SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-09 | — | — | EP | disclosed |
| US-8937096-B2 | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-20 | — | — | US | disclosed |
| US-8853263-B2 | Co-therapy for the treatment of epilepsy and related disorders | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-07 | — | — | US | disclosed |
| EP-1968572-B1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF SUBSTANCE ABUSE AND ADDICTION | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-06 | — | — | EP | disclosed |
| EP-2276481-B1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF ANXIETY | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-30 | — | — | EP | disclosed |
| US-8716231-B2 | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-06 | — | — | US | disclosed |
| US-8497298-B2 | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels | JANSSEN PHARMACEUTICA NV (BE) | 2013-07-30 | — | — | US | disclosed |
| US-8492431-B2 | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-07-23 | — | — | US | disclosed |
| EP-2150249-B1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MIGRAINE | JANSSEN PHARMACEUTICA NV (BE) | 2013-04-24 | — | — | EP | disclosed |
| EP-1976507-B1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPTOGENESIS | JANSSEN PHARMACEUTICA NV (BE) | 2012-09-05 | — | — | EP | disclosed |
| WO-2007075752-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007075833-A2 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF OBESITY | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007075834-A2 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPSY | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007075751-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-05 | — | — | WO | disclosed |
| US-20070155824-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR DISEASE MODIFICATION / EPILEPTOGENESIS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | US | disclosed |
| EP-1768970-A1 | SULFAMATE AND SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-04 | — | — | EP | disclosed |
| US-20060041008-A1 | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-23 | — | — | US | disclosed |
| WO-2006007436-A1 | SULFAMATE AND SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-01-19 | — | — | WO | disclosed |
| WO-2006007435-A1 | SULFAMATE AND SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-01-19 | — | — | WO | disclosed |
| US-20050282887-A1 | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | JANSSEN PHARMACEUTICA NV (BE) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155824-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR DISEASE MODIFICATION / EPILEPTOGENESIS | STS, GABRB2, SULT2A1 | CA2 826/4885PRKAB2 3284/4885PRKAG1 3557/4885 |
| US-20060041008-A1 | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | SULT2A1, STS, GRIK5 | CA2 917/4885PRKAB2 2187/4885PRKAG1 2037/4885 |
| US-20050282887-A1 | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | SULT2A1, STS, GRIK5 | CA2 917/4885PRKAB2 2187/4885PRKAG1 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.